Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Body Dysmorphic Disorder and Risperidone Abuse: Exploiting Hyperprolactinemia

  • Omer Faruk Bulut (Department of Child and Adolescent Psychiatry, University of Health Sciences Turkiye, Bakirkoy Dr. Sadi Konuk Training and Research Hospital)
  • Received : 2025.02.10
  • Accepted : 2025.04.15
  • Published : 2025.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

This case report describes a 16-year-old female with body dysmorphic disorder (BDD), tics, and social withdrawal who intentionally abused risperidone to exploit its hyperprolactinemia-induced breast enlargement, perceiving it as beneficial to her body image. Initial treatment with sertraline improved social withdrawal; however, adjunctive risperidone (0.5 mg/day) reduced tics and BDD symptoms. Elevated prolactin levels (44.85 ng/mL) triggered breast enlargement, galactorrhea, and secondary amenorrhea. The patient continued risperidone despite medical advice to discontinue it. Switching to aripiprazole normalized prolactin levels (9.13 ng/mL) and resolved the side effects, with sustained symptom control at 3-month follow-up. This case highlights the risk of antipsychotic side effects reinforcing BDD pathology and adolescents' vulnerability to medication abuse when somatic changes align with dysmorphic goals. To the best of our knowledge, this is the first report of deliberate risperidone abuse for cosmetic hyperprolactinemia in BDD. Clinicians must monitor prolactin levels, prioritize prolactin-sparing agents (e.g., aripiprazole), and consider how adverse effects may perpetuate body image disturbances in adolescents.

Keywords

References

  1. Rück C, Mataix-Cols D, Feusner JD, Shavitt RG, Veale D, Krebs G, et al. Body dysmorphic disorder. Nat Rev Dis Primers 2024;10:92.
  2. Veale D, Gledhill LJ, Christodoulou P, Hodsoll J. Body dysmorphic disorder in different settings: a systematic review and estimated weighted prevalence. Body Image 2016;18:168-186.
  3. Phillips KA, Atala KD, Albertini RS. Case study: body dysmorphic disorder in adolescents. J Am Acad Child Adolesc Psychiatry 1995;34:1216-1220.
  4. Hong K, Nezgovorova V, Uzunova G, Schlussel D, Hollander E. Pharmacological treatment of body dysmorphic disorder. Curr Neuropharmacol 2019;17:697-702.
  5. Stojkovic M, Radmanovic B, Jovanovic M, Janjic V, Muric N, Ristic DI. Risperidone induced hyperprolactinemia: from basic to clinical studies. Front Psychiatry 2022;13:874705.
  6. Madhusoodanan S, Moise D. Risperidone-induced hyperprolactinemia in adolescents: a case series. J Clin Psychiatry 2006;67:1110-1113.
  7. Monzani B, Fallah D, Rautio D, Gumpert M, Jassi A, Fernández de la Cruz L, et al. Psychometric evaluation of the Yale-Brown obsessive-compulsive scale modified for body dysmorphic disorder for adolescents (BDD-YBOCS-A). Child Psychiatry Hum Dev 2023; 54:1799-1806.
  8. Loréa N, Van Wijnendaele R. [Body dysmorphic disorder and psychosis. Case reports and discussion]. Encephale 2012;38:37-41. French
  9. Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995;34:1147-1152.
  10. Aboraya A, Fullen JE, Ponieman BL, Makela EH, Latocha M. Hyperprolactinemia associated with risperidone: a case report and review of literature. Psychiatry (Edgmont) 2004;1:29-31.
  11. Kopecek M, Bares M, Horacek J, Mohr P. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. Neuro Endocrinol Lett 2006;27:803-806.
  12. Belhadga H, Elmaataoui Z, Kisra H. Management of risperidoneinduced hyperprolactinemia in children: a case report. Eur Psychiatry 2023;66:S509-S509.
  13. Sucupira E, De Brito M, Leite AT, Aihara E, Neto MS, Ferreira LM. Body dysmorphic disorder and personality in breast augmentation: the big-five personality traits and BDD symptoms. J Plast Reconstr Aesthet Surg 2022;75:3101-3107.